{"entity":{"id":"louise-emmett","kind":"person","name":"Louise Emmett","aka":[],"tldr":"Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.","summary":"Louise Emmett (St Vincent's Hospital, Sydney) was principal investigator of ENZA-p, the ANZUP trial showing that adding 177Lu-PSMA-617 to enzalutamide delays progression in castration-resistant prostate cancer, and led the PRIMARY study of PSMA PET for diagnosis. She co-leads the ANZUP theranostics programme and writes widely used guidance on PSMA PET reporting.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA"}],"tags":["prostate","radioligand","australia"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["garvan-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology"],"dependsOn":[],"notes":[],"role":"Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney; Professor, UNSW","institutionId":"garvan-institute","specialisms":["PSMA theranostics","Nuclear medicine","Prostate cancer imaging","Radioligand trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA"}],"papers":[{"title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","journal":"Lancet Oncology","year":2024},{"title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY)","journal":"European Urology","year":2021,"doi":"10.1016/j.eururo.2021.08.002"}],"orcid":"0000-0002-4895-7384"},"route":"/people/louise-emmett/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"institution":[{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/"}],"journal":[{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/"}]}}